Mohamed F El-Ashry, Bal Dhillon. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Angiogenesis Inhibitors/administration & dosageAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal, HumanizedBevacizumabEndophthalmitis/epidemiologyEndophthalmitis/microbiologyEye Infections, Bacterial/epidemiologyEye Infections, Bacterial/microbiologyHumansIncidenceInjectionsRanibizumabStaphylococcal Infections/epidemiologyStaphylococcal Infections/microbiologyStaphylococcus epidermidis/isolation & purificationStreptococcal Infections/epidemiologyStreptococcal Infections/microbiologyStreptococcus mitis/isolation & purificationVascular Endothelial Growth Factor A/antagonists & inhibitorsViridans Streptococci/isolation & purificationVitreous Body/microbiology
Substances： See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor ABevacizumabRanibizumab
Year: 2009 PMID： 19430287 DOI： 10.1097/IAE.0b013e3181a57fa5
Source DB: PubMed Journal: Retina ISSN： 0275-004X Impact factor: 4.256